XOMA Royalty (XOMA) Tax Provisions (2011 - 2026)
XOMA Royalty (XOMA) reported Tax Provisions of $1000.0 for Q1 2026, down 98.15% sequentially from $54000.0 in Q4 2025.
XOMA Royalty (XOMA) Tax Provisions (2011 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 9 years of Tax Provisions data on file, last reported at $1000.0 in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Mar 2026 stood at $146000.0 (changed N/A YoY), and the FY2025 full-year result was $103000.0, up 101.82% from the prior year.
- Tax Provisions slipped to $1000.0 in Q1 2026, from $54000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $54000.0 in Q4 2025 to a low of $1000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 125,146.46 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 31.86 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 221.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -60.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | 54,000.00 |
| Dec 31, 2021 | 91,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 26,000.00 |
| Mar 31, 2020 | -1.53 Mn |
| Dec 31, 2018 | -98,000.00 |
| Dec 31, 2017 | -44,000.00 |
| Sep 30, 2017 | 1.71 Mn |
| Dec 31, 2013 | 1,000.00 |
| Sep 30, 2013 | -15,000.00 |
| Sep 30, 2012 | -74,000.00 |
| Mar 31, 2011 | 15,000.00 |